Medicinal lavender modulates the enteric microbiota to protect against Citrobacter rodentium-induced colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 303, Issue 7, 2012, Pages

  Baker, J ^a   Brown, K ^a   Rajendiran, E ^a   Yip, A ^a   DeCoffe, D ^a   Dai, C ^a   Molcan, E ^a   Chittick, S A ^a   Ghosh, S ^a   Mahmoud, S ^a   Gibson, D L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Colonic inflammation; Enteric microflora; Inflammatory bowel disease; Monoterpenes

Indexed keywords

BORNEOL; CAMPHOR; CINEOLE; CXCL2 CHEMOKINE; ESSENTIAL OIL; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 22; LAVENDER OIL; LINALOOL; LINALYL ACETATE; MINERAL OIL; OKANAGAN LAVENDER ESSENTIAL OIL; TERPENOID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL ADHESION; CELL GROWTH; CHEMICAL COMPOSITION; CITROBACTER RODENTIUM; COLITIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; FIRMICUTES; GAMMAPROTEOBACTERIA; GROWTH INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE FLORA; INTESTINE INJURY; LAVANDULA INTERMEDIA; LAVENDER; MACROPHAGE; MEDICINAL PLANT; MORBIDITY; MORTALITY; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; CHEMOKINE CXCL2; CITROBACTER RODENTIUM; COLITIS; COLON; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INTERFERON-GAMMA; INTERLEUKINS; LAVANDULA; MACROPHAGES; METAGENOME; MICE; MICE, INBRED C57BL; MONOTERPENES; NITRIC OXIDE SYNTHASE TYPE II; PLANT OILS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867188603     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00327.2011     Document Type: Article

References (72)

1. Alam C, Valkonen S, Palagani V, Jalava J, Eerola E, Hanninen A. Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change. Diabetes 59: 2237-2246, 2010.
2. Amann RI, Krumholz L, Stahl DA. Fluorescent-oligonucleotide probing of whole cells for determinative, phylogenetic, and environmental studies in microbiology. J Bacteriol 172: 762-770, 1990.
3. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14: 275-281, 2008.
4. Barman M, Unold D, Shifley K, Amir E, Hung K, Bos N, Salzman N. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 76: 907-915, 2008.
5. Barocelli E, Calcina F, Chiavarini M, Impicciatore M, Bruni R, Bianchi A, Ballabeni V. Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon "Grosso" essential oil. Life Sci 76: 213-223, 2004.
6. Bergstrom KS, Guttman JA, Rumi M, Ma C, Bouzari S, Khan MA, Gibson DL, Vogl AW, Vallance BA. Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen. Infect Immun 76: 796-811, 2008.
7. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 6: e1000902, 2010.
8. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 101: 1559-1568, 2006.
9. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 16: 164-171, 2007.
10. Cavanagh HM, Wilkinson JM. Biological activities of lavender essential oil. Phytother Res 16: 301-308, 2002.
11. Crohn's and Colitis Foundation of Canada. The Burden of Inflammatory Bowel Disease (IBD) in Canada. Toronto, ON, Canada: Crohn's and Colitis Foundation of Canada, 2008.
12. Cosnes J, Seksik P. [Inflammatory bowel disease: from sulfasalazine to biologics]. Gastroenterol Clin Biol 33: 692-701, 2009.
13. Deloris Alexander A, Orcutt RP, Henry JC, Baker J Jr, Bissahoyo AC, Threadgill DW. Quantitative PCR assays for mouse enteric flora reveal strain-dependent differences in composition that are influenced by the microenvironment. Mamm Genome 17: 1093-1104, 2006.
14. Desautels A, Biswas K, Lane A, Boeckelmann A, Mahmoud SS. Suppression of linalool acetate production in Lavandula intermedia. Nat Prod Commun 4: 1533-1536, 2009.
15. Duke J. Handbook of Medicinal Herbs. Boca Raton, FL: CRC, 2002.
16. Eckmann L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann NY Acad Sci 1072: 28-38, 2006.
17. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66: 246-256, 2002.
18. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104: 13780-13785, 2007.
19. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131: 33-45, 2007.
20. Ghosh S, Dai C, Brown K, Rajendiran E, Makarenko S, Baker J, Ma C, Halder S, Montero M, Ionescu VA, Klegeris A, Vallance BA, Gibson DL. Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. Am J Physiol Gastrointest Liver Physiol 301: G39-G49, 2011.
21. Gibson DL, Ma C, Bergstrom KS, Huang JT, Man C, Vallance BA. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol 10: 618-631, 2008.
22. Gibson DL, Ma C, Rosenberger CM, Bergstrom KS, Valdez Y, Huang JT, Khan MA, Vallance BA. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol 10: 388-403, 2008.
23. Gibson DL, Montero M, Ropeleski MJ, Bergstrom KS, Ma C, Ghosh S, Merkens H, Huang J, Mansson LE, Sham HP, McNagny KM, Vallance BA. Interleukin-11 reduces TLR4-induced colitis in TLR2- deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139: 1277-1288, 2010.
24. Gibson DL, Montero M, Vallance BA. Innate immunity and microbes: conversations with the gut leading to intestinal tissue repair and fibrosis. Antiinflammatory Antiallergy Agents Med Chem 8: 228-247, 2009.
25. Goncalves NS, Ghaem-Maghami M, Monteleone G, Frankel G, Dougan G, Lewis DJ, Simmons CP, MacDonald TT. Critical role for tumor necrosis factorin controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun 69: 6651-6659, 2001.
26. Grieve M. A Modern Herb. London: Cape, 1931.
27. Gruenwald J. PDR for Herbal Medicine. Montvale, NJ: Medical Economics, 1998.
28. Guri AJ, Hontecillas R, Bassaganya-Riera J. Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. Clin Nutr 29: 824-831, 2010.
29. Hajhashemi V, Ghannadi A, Sharif B. Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of Lavandula angustifolia Mill. J Ethnopharmacol 89: 67-71, 2003.
30. Harmsen HJM, Elfferich P, Schut P, Welling GW. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in fecal samples by fluorescent in situ hybridization. Microbial Ecol Health Dis 11: 3-11, 1999.
31. Heilig HG, Zoetendal EG, Vaughan EE, Marteau P, Akkermans AD, de Vos WM. Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl Environ Microbiol 68: 114-123, 2002.
32. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485-498, 2009.
33. Juhas S, Cikos S, Czikkova S, Vesela J, Il'kova G, Hajek T, Domaracka K, Domaracky M, Bujnakova D, Rehak P, Koppel J. Effects of borneol and thymoquinone on TNBS-induced colitis in mice. Folia Biol (Praha) 54: 1-7, 2008.
34. Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 16: 2034-2042, 2010.
35. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5: 1424-1429, 2007.
36. Khan MA, Bouzari S, Ma C, Rosenberger CM, Bergstrom KS, Gibson DL, Steiner TS, Vallance BA. Flagellin-dependent and -independent inflammatory responses following infection by enteropathogenic Escherichia coli and Citrobacter rodentium. Infect Immun 76: 1410-1422, 2008.
37. Khan MA, Ma C, Knodler LA, Valdez Y, Rosenberger CM, Deng W, Finlay BB, Vallance BA. Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect Immun 74: 2522-2536, 2006.
38. Kim HM, Cho SH. Lavender oil inhibits immediate-type allergic reaction in mice and rats. J Pharm Pharmacol 51: 221-226, 1999.
39. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury: agents of defense or destruction? Annu Rev Pharmacol Toxicol 51: 267-288, 2011.
40. Luperchio SA, Schauer DB. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect 3: 333-340, 2001.
41. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2: 204, 2007.
42. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 48: 386-388, 2009.
43. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 265-267, 2007.
44. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205-211, 2006.
45. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 70: 7220-7228, 2004.
46. Meier H, Amann R, Ludwig W, Schleifer KH. Specific oligonucleotide probes for in situ detection of a major group of gram-positive bacteria with low DNA G C content. Syst Appl Microbiol 22: 186-196, 1999.
47. Murphy CT, Moloney G, Hall LJ, Quinlan A, Faivre E, Casey P, Shanahan F, Melgar S, Nally K. Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis. Clin Exp Immunol 162: 188-196, 2010.
48. Nelson RR. In-vitro activities of five plant essential oils against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 40: 305-306, 1997.
49. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446: 557-561, 2007.
50. O'Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. Sci World J 7: 31-46, 2007.
51. Ogino H, Nakamura K, Iwasa T, Ihara E, Akiho H, Motomura Y, Akahoshi K, Igarashi H, Kato M, Kotoh K, Ito T, Takayanagi R. Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. J Gastroenterol 47: 366-376, 2012.
52. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 22: 292-301, 2009.
53. Peana AT, D'Aquila PS, Panin F, Serra G, Pippia P, Moretti MD. Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils. Phytomedicine 9: 721-726, 2002.
54. Peris-Bondia F, Latorre A, Artacho A, Moya A, D'Auria G. The active human gut microbiota differs from the total microbiota. PLos One 6: e22448.
55. Petnicki-Ocwieja T, Hrncir T, Liu YJ, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, Kobayashi KS. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 106: 15813-15818, 2009.
56. Ramakrishna BS, Roediger WE. Bacterial short chain fatty acids: their role in gastrointestinal disease. Dig Dis 8: 337-345, 1990.
57. Santos FA, Silva RM, Campos AR, De Araujo RP, Lima Junior RC, Rao VS. 1,8-Cineole (eucalyptol), a monoterpene oxide, attenuates the colonic damage in rats on acute TNBS-colitis. Food Chem Toxicol 42: 579-584, 2004.
58. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Dore J. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52: 237-242, 2003.
59. Shiomi H, Masuda A, Nishiumi S, Nishida M, Takagawa T, Shiomi Y, Kutsumi H, Blumberg RS, Azuma T, Yoshida M. Interferon produced by antigen-specific CD4 T cells regulates the mucosal immune responses to Citrobacter rodentium infection. Infect Immun 78: 2653-2666, 2010.
60. Simmons CP, Goncalves NS, Ghaem-Maghami M, Bajaj-Elliott M, Clare S, Neves B, Frankel G, Dougan G, MacDonald TT. Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-. J Immunol 168: 1804-1812, 2002.
61. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105: 16731-16736, 2008.
62. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Dore J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15: 1183-1189, 2009.
63. Sosa S, Altinier G, Politi M, Braca A, Morelli I, Della Loggia R. Extracts and constituents of Lavandula multifida with topical anti-inflammatory activity. Phytomedicine 12: 271-277, 2005.
64. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 298: 463-472, 2008.
65. Tobe T, Sasakawa C. Species-specific cell adhesion of enteropathogenic Escherichia coli is mediated by type IV bundle-forming pili. Cell Microbiol 4: 29-42, 2002.
66. Ungaro R, Fukata M, Hsu D, Hernandez Y, Breglio K, Chen A, Xu R, Sotolongo J, Espana C, Zaias J, Elson G, Mayer L, Kosco-Vilbois M, Abreu MT. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 296: G1167-G1179, 2009.
67. Vallance BA, Deng W, Jacobson K, Finlay BB. Host susceptibility to the attaching and effacing bacterial pathogen Citrobacter rodentium. Infect Immun 71: 3443-3453, 2003.
68. Vermeiren J, Van den Abbeele P, Laukens D, Vigsnaes LK, De Vos M, Boon N, Van de Wiele T. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol 79: 685-696, 2012.
69. Wagner M, Amann R, Lemmer H, Schleifer KH. Probing activated sludge with oligonucleotides specific for proteobacteria: inadequacy of culture-dependent methods for describing microbial community structure. Appl Environ Microbiol 59: 1520-1525, 1993.
70. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322, 1322 e1311-1315, 2011.
71. Walter J, Hertel C, Tannock GW, Lis CM, Munro K, Hammes WP. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Appl Environ Microbiol 67: 2578-2585, 2001.
72. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, Ouyang W. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282-289, 2008.